Artilysin
Pre-clinical- Indications
- Bacterial infections, Acne, Atopic dermatitis, Wound infections
Company intelligence / Profile preview
Lysando AG
Triesenberg, Liechtensteinlysando.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Lysando's lead candidate Art-175 is in preclinical development for Gram-Positive Bacterial Infections. The company has developed over 450 effective prototypes demonstrating Artilysin's potential for treating various bacterial infections.
- Therapeutic areas
- PulmonologyDermatologyInfectious Diseases
- Modalities
- Antimicrobial proteins (Artilysin® molecules)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
AiCuris Anti-infective Cures GmbHAmicogen (South Korea)Bamberg UA (Non-Profit Organization)
Beyond the preview
Go deeper on Lysando AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lysando AG.